MONTREAL, Nov. 13, 2025 /CNW/ - Myeloma Canada welcomes the Canadian Drug Agency's (CDA) two positive recommendations for the reimbursement of Blenrep (R) (belantamab mafodotin) -- a critical new ...

For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, ...

The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

Since the beginning of this century, advances in understanding the biology of multiple myeloma have transformed the disease ...

Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...

The FDA approves Johnson & Johnson's Darzalex Faspro for high-risk smoldering multiple myeloma and Caplyta as an add-on ...

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell ...

The approval for HR-SMM was based on data from the phase 3 AQUILA study, which evaluated Darzalex Faspro in adults aged 31 years and older with HR-SMM.